When a child is diagnosed with cancer, one of the first questions the parents ask is “Will my other children get cancer?” A new study from Huntsman Cancer Institute (HCI) at the University of Utah suggests the answer to that question depends on whether a family history of cancer exists. The research results were published online in the International Journal of Cancer and will appear in the November 15 print issue.
The study, led by Joshua Schiffman, M.D., medical director of HCI’s High Risk Pediatric Cancer Clinic and a pediatric hematologist/oncologist in in the Department of Pediatrics at the University of Utah, examined the family medical history of 4,482 children diagnosed with cancer over a 43-year period to determine the cancer risk in their relatives.
The research team found that when children were diagnosed with any kind of cancer at age 18 or younger, the risk to their parents, siblings, or children for childhood cancer doubled compared to families with no childhood cancer patients. If the cancer diagnosis came when the child was age 4 or less, the risk to close relatives for childhood cancer increased almost four times.
“No one had previously studied the question, so we simply told parents there was no evidence of increased risk to the other children,” said Schiffman. “Now we can give an evidence-based answer — the risk depends on your family history of cancer.”
This is the first study that uses the Utah Population Database (UPDB) to broadly examine the risk of all types of cancer in relatives of children with cancer. This unique resource at the University of Utah links genealogies and cancer registry data from Utah to medical records and vital records, including Utah death certificates.
“Because our data came from the UPDB, the assessment of family history in our study does not rely on self- or family-reported medical history,” said lead author Karen Curtin, Ph.D., a genetic epidemiologist and UPDB assistant director. “Self-reporting of family medical history depends on an individual’s memory, while our data comes from the statewide Utah Cancer Registry that records nearly all cancer cases, which reduces possible errors in reporting family cancers.”
The team also assessed known inherited genetic syndromes in adult relatives of pediatric cancer patients. They found cancers associated with Li-Fraumeni Syndrome (LFS) seemed to be driving the increased risk to relatives in families with a history of cancer.
“Not all children’s cancers are hereditary,” said Schiffman. “But the numbers in this study suggest that the proportion of hereditary childhood cancers may be significantly higher than the 5-10% generally cited in adult hereditary cancers, and likely even more than 20%.
“LFS is one of the most devastating cancer syndromes,” said Schiffman. “It causes a variety of cancers in both children and adults. For people with LFS, the lifetime risk of getting cancer is 80% to 90%, but with increased and early screening for tumors, there’s early indication of a very high survival rate, perhaps even approaching100%. In a previous study, LFS patients who did not receive early screening only had a 20% survival rate.”
Although childhood cancer rarely occurs in the population, based on their findings, the authors recommended collection of three generations of family medical history for all newly diagnosed pediatric cancer patients and referral of families with a history of early-onset cancers in children or adults for genetic counseling. In addition, parents of children diagnosed with cancer before age five with a family history of cancer should be advised of the potential for increased risk to other children in the family.
“We want to encourage the taking of a family history as part of routine care. With all cancers, but perhaps especially with childhood cancers, so many other questions seem so urgent, a family history may not seem to be the most pressing issue,” said co-author Wendy Kohlmann, director of HCI’s Genetic Counseling Program. “When families are referred into genetic counseling, we can provide them with more information about the risks and actions they can take.”
“For families with previously unidentified LFS, following these recommendations could actually save the lives of multiple family members if at risk individuals are identified and early cancer surveillance programs implemented,” Schiffman said.
A guest blog from Georgia Hurst, as she worries about the impact of her diagnosis of Lynch Syndrome on her son. Read more at ihavelynchsyndrome.com
“I will not get sick, but if I do…
…I will have the strength to endure it.”
This is my new mantra. The above photo is the view from my zafu when I go to Buddhist Temple for meditation; the solace this gives me is immeasurable. I have been finding myself at Temple a lot lately, meditating and reaching for my internal strength to deal with the unbearable anxiety and stress which currently confront me. I’m trying not to discuss it with people; it’s too much for me to process, let alone them. Besides, I feel as though I put them into a precarious position if I do bring it up because there are no words available to them which can possibly comfort me at this time. I am going to Mayo Clinic in 11 days and the anxiety is increasing by the minute. I am expecting the worst, whilst hoping for the best. I’m sure I am not the only one with Lynch syndrome that feels this way when it’s close to testing time. The plethora of emotions are running rampant in me little head. I feel guilt. My oldest brother did not have a chance, my second brother does not have a colon – and then I think of all of the people I’ve met through my blog and Facebook and other forms of social media who are fighting for their lives because they, too, have been blindsided by this genetic curse. Damn you, Lynch syndrome. I feel anger because I may have given this to my beautiful little boy. If I knew for sure that this monster ended with me with 100% certainty, I would at least not have to fret about my child. I also feel anger for all the children who are watching their parents suffer and die, leaving them with a life of endless uncertainties and insecurities. I feel sad, not for myself, but for my family, my dog, and my friends; because I know that part of you dies when someone you love dies. I feel lucky; I’m fortunate to know I have this genetic mutation, have insurance, and have the ability to exhibit some control of it; I get to go Mayo and get see the Rock Star Doctors of Lynch syndrome. I feel confident; I keep reminding myself that I eat well, exercise, surround myself with loving, nourishing people, animals, books, etc., and have eliminated every imaginable toxin in my life. I feel fearless and empowered in many ways; yet, helpless in so many others. I vacillate between optimism and negativity; perhaps I should simply stop it and end up somewhere in the middle. I am exhausted, whilst I exhibit every possible emotion known to humanity. I long for the days when I didn’t know of my charming genetic nemesis and wasn’t emotionally imprisoned by Lynch syndrome. I would give everything I have to simply appreciate a few minutes of life sans Lynch. Two weeks from today, I will know if everything I talk about truly matters or if my genetics will trump everything I think and do. I just want spend the next several days being fearless. Fearless. Fearless. Fearless. In the eloquent words of Tagore: Let me not pray to be sheltered from dangers but to be fearless in facing them. Let me not beg for the stilling of my pain but for the heart to conquer it. Let me not look for allies in life’s battlefield but to my own strength. Let me not cave in… Yours, Georgia Hurst, MA ihavelynchsyndrome.com This post was written in late April before I went to the Mayo Clinic in early May for my annual testing; I received a clean bill of health and not even one little polyp was found in my colon.
Thanks to Georgia Hurst for this insightful article based on her personal experiences as someone diagnosed with Lynch Syndrome. She describes some of the barriers she has faced with this diagnosis. Her blog is available at ihavelynchsyndrome.com
Matroyoshka Nesting Dolls by Georgia Hurst – ihavelynchsyndrome.com
I cannot help but think of those adorable Matryoshka nesting dolls when considering Lynch syndrome and its implications. Matryoshka nesting dolls are those cute, wooden Russian figures which separate, top from bottom, to reveal a smaller figure of the same sort inside, which, in turn, reveals another figure inside that, and so on. I think of those dolls as a metaphor for Lynch syndrome, sans the cuteness. The emotional toll of knowing you hold a deleterious gene mutation can be quite challenging and one Lynch syndrome issue leads to another, to another, and so forth. With that introduction, I am simply trying to raise consciousness in the elusive Lynch syndrome world about topics which are rarely discussed amongst the professionals who deal with Lynch syndrome patients. Doctors, genetic counselors, psychiatrists, psychologists, and others need to be cognizant that people with Lynch syndrome are dealing with a constellation of emotional and possibly physiological issues as a result of this diagnosis and the recommended surgeries.
Lynch syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer: HNPCC, affects approximately 600,000 people in the United States; yet, only approximately only 5% of us know it. Lynch syndrome is typically associated with a significantly increased risk for colorectal and endometrial cancers and is caused by mutations in following genes: MLH1, MSH2, MSH6, PMS2, and EPCAM. Cancers potentially stemming from Lynch syndrome include: colorectal, endometrial, gastric, ureter/renal, pelvis, biliary tract, small bowel, pancreas, brain, sebaceous carcinomas ovarian, prostate in men, and breast, endometrial and ovarian cancer in women. Lynch syndrome warning signs include early onset cancers (<50y) in one’s family history, specifically colon cancer, endometrial cancer, and/or two or more other cancers in the same individual, or among their close relatives.
My Lynch Matryoshka dolls exposed a plethora of new challenges and I did not have even one of those cancers. I took the prophylactic measure of removing my reproductive organs to prevent malignancy to them and was fortunate enough to ‘only’ have a hysterectomy and bilateral salpingo-oophorectomy. At the time of the surgery, I was a healthy, fit 40-year-old-woman – ten years, or more, away from menopause and doctors completely minimized what was to happen to me with this surgery, assuming that the “one size fits all approach” to medicine would with work with me. I was told that a hysterectomy and bilateral salpingo-oophorectomy were not such a big deal for a woman of my age and that I would be fine with a low dose of estrogen and an antidepressant. Unbeknownst to me, my physiological and psychological response to the surgery would end up highly taxing to say the least. The convalescence from surgery and further testing for Lynch syndrome screenings required a number of doctors’ visits – to some doctors who did not know about Lynch syndrome, nor would they take the time to find out, or were too arrogant to refer me elsewhere. A physician’s lack of knowledge regarding a deleterious gene mutation can only fuel a patient’s existing fears and anxiety. It is comparable to throwing the patient into dark, shark infested waters, and not telling them which way to swim; a very frightening position to be in for a person who already feels like a walking time bomb.
My first, big doll is the Lynch diagnosis of MLH1 followed by the dolls of: doctors who do not know what Lynch syndrome entails; depression; anxiety (especially over the thought of the gene mutation being passed onto my child); surgery; hormone replacement (over several months); antidepressants (and their charming side effects); hot flashes; frustration over family members ignoring pleas to get tested; loss of appetite; lethargy; stressors on family; personality changes; feelings of despair, isolation, frustration, anger; insomnia; debilitating nausea; vomiting; headaches; hair loss; and the anxiety of annual testing. Each doll is either an emotional manifestation of knowing I have Lynch syndrome, or a physical manifestation of the prophylactic surgery, and occasionally, a doll can be a result of both.
I am not your typical patient and am probably considered an anomaly in the medical world as far as patients are concerned; I have always been vigilant with my health due to my extensive background in biology and have become my greatest advocate against Lynch syndrome. Even though I live in Chicago and have access to exceptional healthcare, I still had to find doctors who knew more about Lynch than I did. Of course, I know there are thousands of genetic mutations, I could not expect every doctor to be familiar with every single one, but there should be some measure in place for physicians, at the very least, to provide patients in such precarious circumstances with some level of care, whether it be a referral, or through some other form of support. A number of doctors I sought out for the various required screenings did not know what Lynch syndrome entails and what screening involves, or bothered to find out. Frustrated I sought a referral from a friend of mine, who happens to be a neurologist; he referred me to one of the top oncologists in Chicago, and thought this oncologist could help me in taking preventative measures against Lynch syndrome. They knew I was there for Lynch syndrome and yet the oncologist had not known, or researched Lynch syndrome prior to my visit, and told me there was nothing they could do for me. I refused to believe them and continued my search beyond Chicago.
Through research, I found a specialist at Mayo Clinic and have the good fortune to visit her and the rest of my ‘team’ on an annual basis. I make one phone call when need to come in for my annual testing for Lynch syndrome and they take care of the rest. My screening at Mayo Clinic consists of: a CT scan, an annual colonoscopy, an upper endoscopy with extended duodenoscopy, CA-125, a urinalysis with cytology and renal ultrasound, a mammogram, and a dermatological exam to screen for sebaceous adenomas, carcinomas, keratoacanthomas. Currently there is no screening for brain cancer because the screening modality for it has not been shown to be effective at detecting cancers early or reducing morbidity and mortality if detected early. The physicians at Mayo know which tests to conduct, how frequently they must be done, which doctors are best suited for each test, and are capable of completing the various scopes and tests within of two days. My medical care requires a huge collaboration amongst doctors who know their stuff. I take great comfort in knowing that I am in stellar hands, within the confines of leading medical facility, and this in turn relieves a great deal of my anxiety.
This combination of specialists, each highly knowledgeable about Lynch syndrome, and who can discuss each patient’s unique circumstance among themselves is, I have found, an exceptional reassurance. I hope that many more such ‘teams’ will be set up for those who have Lynch syndrome.
There are several proactive measures one can take to prevent cancer and influence their gene expression.
I believe, and mounting evidence supports this, there is a constellation of factors regarding whether or not one develops cancer. Along with annual screenings and stellar medical care, I believe a healthy plant-based diet, exercise, stress reduction, meditation, and a sanguine personality will combat my deleterious gene mutation. There are many factors which effect your gene expression and whether or not you survive cancer, and I use Stephen J. Gould as my best model.
Gould was an esteemed evolutionary biologist from Harvard and was diagnosed with peritoneal mesothelioma and even with surgery, his prognosis was not good – according to the statistics, those with this particular disease typically have eight months to live. Fortunately, his professional training as an evolutionary biologist required a strong familiarity with statistics and he knew how to decipher the data. This inspired him to write an article for Discover magazine entitled, The Median Isn’t the Message, discussing how statistical averages are simply abstractions – they do not include the full range of variation. Gould applied this thinking to his medical situation and figured out that his circumstances would put him in the upper statistical range for a number of reasons: his cancer was detected early, he was young, had access to great medical care, possessed a positive attitude and was willing to take risks with experimental treatments. Gould managed to survive for 20 years until another cancer, metastatic adenocarcinoma of the lung, ended his life on May 20, 2002. His story and thoughts have been inspirational for many cancer patients.
My most recent Lynch doll was the result of the psychological toll of knowing I have Lynch syndrome. The physiological toll and the physicians’ minimization of having the oophorectemy at a young age, and having experienced menopausal shock, prompted me to create a website called: ihavelynchsyndrome.com. I have tried to create a site mostly for previvors, people who have Lynch syndrome but do not have cancer; a site I would have liked to have found when I was diagnosed, where nothing is sugar-coated and where others may seek validation for the myriad of emotions as a result of the diagnosis. I deal with the daily, complex, emotional aspects of having a deleterious gene mutation; and yet, at the same time, try to provide my readers with some solace and encourage them to make positive changes to their lifestyle. My most recent doll has provided me with a cathartic outlet, whilst helping others who are coming to terms with their diagnosis. It has provided me with a platform to give a voice to an elusive, heinous syndrome, which can be controlled to some degree, with endless vigilance, screenings and living well.
Georgia Hurst, MA
Georgia Hurst’s blog: Ihavelynchsyndrome.com
TRIPLER ARMY MEDICAL CENTER, Hawaii, USA – Daniel Shockley, a retired Sailor living on Oahu, meets with Lt. Col. Ronald Gagliano, chief, Colon and Rectal Surgery and director, Surgical Research, TAMC, to discuss recovery and post-operative…
Due to his hectic work schedule, Shockley rescheduled the screening a couple times and it wasn’t until May 8, 2012, when he got the colonoscopy.
“They usually schedule colonoscopies for 1-hour blocks of time, but they found so much wrong during mine that he had to spend a lot of time documenting and taking pictures,” Shockley explained. “What they found was approximately 100 polyps embedded throughout my colon, rectum and anus. And at the traverse colon, the junction between the large and small intestine, they found a large tumor that was creating an 80 percent blockage.”
Shockley was referred to Tripler Army Medical Center’s general surgery clinic, and the week following the screening, he met with Susan Donlon, a certified genetic counselor at Tripler.
Donlon performed DNA tests on Shockley and within three weeks the tests had come back confirming that Shockley has a gene mutation known as Adenomatous Polyposis Coli, which increases a person’s risk of developing colorectal cancer. As a result of the mutation, Shockley was diagnosed with Attenuated Familial Adenomatous Polyposis, a condition in which numerous polyps form mainly in the large intestine.
“I knew surgery was inevitable and I was willing to accept the worst case scenario the whole time,” Shockley said.
On July 13, Shockley underwent a total proctocolectomy with ileostomy surgery, which removed portions of his large intestine to include the entire colon, rectum and anus.
Shockley spent about two weeks in Tripler’s general inpatient surgery ward recovering before he was able to go home. It was nine weeks before he was able to go back to work.
Lt. Col. Ronald Gagliano, chief, Colon and Rectal Surgery and director, Surgical Research, TAMC, performed Shockley’s surgery and has followed up with him to ensure he is not only well-informed, but also well-educated.
“He knew nothing of his disease and its many facets before we met and our team (at Tripler) began his personal education in order to promote effective counseling regarding his diagnostic and therapeutic options,” Gagliano explained. “Finally we educated him regarding his genetic situation so that he could choose (how to best) inform his family. By giving him great care, we essentially treat an entire family cohort.”
“(Dr. Gagliano and his team) have passion for what they do, and my care was phenomenal,” Shockley expressed. “I cannot say enough good things about my stay and the care they provided.”
Gagliano is very pleased with Shockley’s recovery thus far and attributes it to his attitude.
“I tend not to think about things I can’t control,” Shockley explained. “Medical issues are not something I can control, but what I can control is my attitude and after 51 years on God’s green earth my positive attitude has gotten me this far and I am not going to change it.”
Because of Shockley’s surgeries, he now has an ostomy pouching system, a prosthetic medical device that provides a means for the collection of waste. Nina Lum, certified wound, ostomy and continence nurse, TAMC, who helped care for Shockley throughout his recovery, echoed Gagliano’s remarks.
“Shockley’s resilience in the face of challenges including his tremendous enthusiasm for life, regardless of setbacks, certainly played a huge role in his recovery,” Lum said. “He has always maintained a positive outlook, been fully engaged in his care from the beginning, reached out to the ostomy community not only for support, but also to offer support and advise based on his personal experience.
“He is selfless in trying to reach out to others,” Lum added.
Shockley has embraced his diagnosis and challenged it from the start. He acts as a patient advocate and an ambassador for colon cancer awareness.
“(I want to) share my story with others on behalf of those patients that have gone before me and who were unable to share their story,” Shockley explained. “My catchphrase is ‘AFAP-Seize the disease!'”
Shockley wants to spread the information about his diagnosis and experience so he can inspire others to get the screening and be aware of the condition. Additionally, there is not a lot of information about AFAP available, so he hopes that talking about his diagnosis will help the medical community.
“By maintaining a positive attitude, the opportunity for a success story is much higher,” Shockley said. “This in turn allows me a better chance of overcoming adversities I am faced with during my lifetime.”
This article provides a historical overview of the online database (www.insight-group.org/mutations) maintained by the International Society for Gastrointestinal Hereditary Tumours (InSiGHT). The focus is on the mismatch repair genes which are mutated in Lynch Syndrome. APC, MUTYH and other genes are also an important part of the database, but are not covered here. Over time, as the understanding of the genetics of Lynch Syndrome increased, databases were created to centralise and share the variants which were being detected in ever greater numbers. These databases were eventually merged into the InSiGHT database, a comprehensive repository of gene variant and disease phenotype information, serving as a starting point for important endeavours including variant interpretation, research, diagnostics and enhanced global collection. Pivotal to its success has been the collaborative spirit in which it has been developed, its association with the Human Variome Project, the appointment of a full time curator and its governance stemming from the well established organizational structure of InSiGHT.
The InSiGHT colorectal cancer hereditary mutation database can be found here
Don’t be embarrassed to go to your GP .
A consultant at West Middlesex University Hospital is urging people to go to their GP if they have symptoms linked to bowel cancer. Dr Kevin Monahan, Consultant Gastroenterologist, runs the Family History of Bowel Cancer Clinic at West Middlesex, and is speaking out to support bowel cancer awareness month during April. He says: “If for the last three weeks you’ve had blood in your poo or it’s been looser, go and see your GP. “We know that people are reluctant to visit their GP if they experience symptoms because they’re embarrassed and worried about wasting the doctor’s time. “But it could save your life. Over 90 per cent of bowel cancer patients diagnosed with the earliest stage of the disease survive five years from diagnosis compared with only 6.6 per cent of those diagnosed with advanced disease. “Bowel cancer is the third most common cancer in the UK for men and the second most common cancer for women. Every year more than 30,000 people will develop it. An estimated 13,000 people die annually from bowel cancer. “Many people worry about getting bowel cancer, sometimes because a relative has had it. At West Middlesex I run a Family History of Bowel Cancer Clinic specifically for those people who may be at higher risk of developing the disease. “The cause of most bowel cancers is not known, but we do know that some risk factors can increase your chances of developing cancer. This includes having one close relative aged under 50 or at least two close relatives on the same side of the family who developed bowel cancer at any age. “If these apply to your family and you’re worried about your risk of developing bowel cancer, you may want to talk to your GP. If your GP thinks there’s a chance you may have an increased risk of developing bowel cancer because of your family history, they can refer you to the Family History of Bowel Cancer Clinic here or elsewhere for advice and treatment.”
Making Universal Screening for a Reality: The Lynch Syndrome Screening Network
March 22nd, 2012 11:35 am ET – From CDC
Deb Duquette, MS, CGC, Sarah Mange, MPH- Michigan Department of Community Health, Cecelia Bellcross, PhD, MS- Emory University, Heather Hampel, MS, CGC- The Ohio State University, Kory Jasperson, MS, CGC- Huntsman Cancer Institute
Authors are all from the Lynch Syndrome Screening Network (LSSN) Founding Board of Directors
flow chart individualEvery day, about 400 people in the United States are diagnosed with colorectal cancerExternal Web Site Icon. Approximately twelve of them have Lynch syndrome, a hereditary condition that increases the risk of colorectal cancer and other cancers. Identifying people with Lynch syndrome could have substantial health benefits for them, their families, and communitiesExternal Web Site Icon.
Lynch syndrome is the most common hereditary cause of colorectal and endometrial cancer; it also leads to increased risks of ovarian, pancreatic, and several other cancers, which often occur at a younger than average age. Lynch syndrome occurs among men and women in all ethnic groups in the United States. A diagnosis of Lynch syndrome offers an opportunity to 1) enhance cancer prevention and screening measures for patients and families, 2) prevent cancer or detect it earlier, and 3) save lives and is cost-effectiveExternal Web Site Icon.
In 2009, the Evaluation of Genomic Applications in Practice and Prevention Working Group published an evidence-based recommendationExternal Web Site Icon that every person newly diagnosed colorectal cancer should be offered screening for Lynch syndrome to identify opportunities to reduce morbidity and mortality in their relatives.
Lynch syndrome screening is performed by analyzing tissue from the person with colorectal cancer for specific pathologic features. If the results suggest the possibility of Lynch syndrome, the affected person is offered genetic counseling and additional testing. Offering screening to all newly diagnosed colorectal cancer patients—regardless of age, ethnicity or family history—is termed “universal screening.” This approach supports an objective of Healthy People 2020, which is to:
‘Increase the number of newly diagnosed colorectal cancer patients who are screened for Lynch syndromeExternal Web Site Icon’
In September 2011, a group of 37 dedicated people from leading cancer institutions created the Lynch Syndrome Screening Network (LSSN)External Web Site Icon, with the goal of reducing the cancer burden associated with Lynch syndrome. LSSN has already received more than 80 institutional applications for membership. More than half of the applicant institutions have already implemented universal Lynch syndrome screening and the others are either interested or in the process. The LSSN will facilitate implementation of universal Lynch syndrome screening by promoting sharing of resources, protocols, and data. LSSN Founding members have already gathered existing educational resources and created a new database to monitor progress toward achieving the Healthy People 2020 objective for Lynch syndrome.
Each first-degree relative (parent, sibling, or child) of a person with Lynch syndrome has a 50% risk of carrying the gene mutation and should be offered genetic counseling and testing. Relatives of a person with Lynch syndrome who are not found to have the gene mutation for Lynch syndrome will typically have the same risk for colorectal cancer as the general population, and their children will not be at risk for Lynch syndrome. Family members who are found to have the gene mutation for Lynch syndrome can be offered earlier and more frequent screening for colorectal and other cancers. Because these people can pass the gene mutation on to their children, the children should also be offered testing after reaching adulthood.
Genetic testing in family members of persons with a Lynch syndrome gene mutation is called “cascade testing.” Cascade testing will allow the Healthy People 2020 objective to achieve population health impact by preventing additional cancers in family members.
March is National Colorectal Cancer Awareness month. This month, increasing awareness of Lynch syndrome is especially timely, as the importance of collecting and sharing information regarding family history of colorectal cancer is being promoted throughout the United States (Colon Cancer AllianceExternal Web Site Icon ; Family PLZExternal Web Site Icon). People with an immediate family member diagnosed with colorectal cancer should share this information with their health care providers, so that screening for Lynch syndrome can be considered.
Lynch Syndrome International is promoting March 22, 2012, as LYNCH SYNDROME PUBLIC AWARENESS DAY. To learn more, please visit Lynch Syndrome International Home pageExternal Web Site Icon ( or the Lynch Syndrome Hereditary Cancers Public Awareness pageExternal Web Site Icon or LSI on FacebookExternal Web Site Icon)
Back in December we wrote about Jeremy Hunt’s announcement that six centres in England would start using Bowel Scope Screening (BSS, also known as flexi-scope or flexible sigmoidoscopy) as part of their bowel screening programme in 2013.
This week, 55 year olds in the South of Tyne region (which includes Gateshead, Sunderland and South Tyneside) received the first wave of letters inviting them to be screened.
This is great news. Cancer Research UK has been involved in Bowel Scope Screening from the beginning – we co-funded a 16 year study which showed that it cuts deaths by over 40 per cent, and – unlike the current test – can actually prevent a third of bowel cancers among those screened.
As a result, it has the potential to save thousands of lives from bowel cancer each year.
As soon as the trial results were published in 2010, we said we wanted the Government to add BSS to the existing bowel screening programme, and later that year, they agreed, setting aside £60m to fund it.
Since then we’ve been calling for Bowel Scope Screening to start as soon as possible, so it’s fantastic to see it finally happen.
The test used in Bowel Scope Screening, flexible sigmoidoscopy , uses a flexible tube with a camera and a light on the end to look into your lower bowel. It can spot both early-stage cancers and pre-cancerous growths known as ‘polyps,’ which can be immediately removed to prevent them developing into cancer.
Recent studies have shown that people find it ‘acceptable’ and ‘reassuring’.
It’s not a new test – it’s been used to diagnose bowel cancer in patients with symptoms for many years. But what is new is using it in this way to screen the population before they even have symptoms. And this could have a huge impact on bowel cancer in this country.
This is the first of six ‘pilot’ centres which will iron out any potential problems in the system before rolling out BSS to the rest of the country. Over the next few months, another five centres will then start to offer Bowel Scope Screening.
By 2016, everyone in England should be invited to have a test at the age of 55.
Bowel Scope Screening adds to the existing bowel screening programme, which uses the Faecal Occult Blood Test (FOBT) – which looks for blood in your stools. People are invited from age 60 to participate (or age 50 in Scotland).
Under the new plans, if you live in England, you’ll be invited to be screened using BSS when you turn 55. If you decide not to go (and it is your decision), you can change your mind up until you turn 60. At that point you’ll be invited to take part in the existing bowel screening programme.
Whether or not you decide to have BSS, you will still be invited to take part in the existing screening programme at 60, to help spot any cancer that might develop later on. Although it hasn’t been shown to prevent cancer in the same way as BSS, FOBT is still an important way of helping to diagnose bowel cancer at an early stage, when treatment is more likely to be successful. The evidence so far suggests it’s made a big impact already and BSS takes this a step further.
This is an important first step. Now we need to make sure that everyone can benefit from Bowel Scope Screening. At the moment BSS is only being rolled out in England. We want to see Scotland, Wales and Northern Ireland develop their own plans for BSS, including making sure they have the right facilities available.
If this test is made available across the UK, thousands of deaths will be prevented, and – even better – potentially thousands of people will be spared from ever having to experience this terrible disease.
A new study1 that combines genetic information on bowel cancer with NHS patient outcome data has found a link between family history of the disease and a better chance of survival, published in the British Journal of Cancer.
Cancer Research UK scientists, based at the University of Leeds, in collaboration with the National Cancer Intelligence Network (NCIN), matched the genetic data2 of nearly 11,000 bowel cancer patients with data from the National Cancer Data Repository (NCDR) on treatment and survival.
And by tracking the survival of these bowel cancer patients they found that the 1,700 people (16 per cent) with a family history of the disease were 11 per cent less likely to die from bowel cancer within 5 years of diagnosis than patients who had no family history of the disease3.
The scientists believe the better prognosis for those with a family history may be linked to the fact that these patients were more likely to have right-sided tumours, that are biologically different to other tumour types, which may respond better to treatment.
Dr Eva Morris, a Cancer Research UK funded scientist at the University of Leeds, and lead author of the research, said: “Our study has found a relationship between family history of bowel cancer and a higher chance of survival.
“Although we haven’t been able to determine exactly why this is the case, it does demonstrate how we can use data that we already routinely collect to help us develop a better understanding of bowel cancer and its genetic causes.
“As datasets such as the NCDR expand and collect more detailed information this opens up the possibility of using this data to help develop better targeted treatments for patients, based upon their individual genetics.”
Dr Julie Sharp, senior science information manager at Cancer Research UK, said: “This is another important step forward in our understanding of bowel cancer. Now we need to find out more about what’s causing this difference. Studies like this, which link genetic data to detailed patient information, may help us develop a more personalised approach to treating cancer in the future.
“Survival from bowel cancer is best when it’s diagnosed and treated in the early stages, so anyone who notices possible symptoms of the disease – blood in stools, or changes to bowel habits lasting longer than three weeks should get this checked out. If you think you may have a family history of bowel cancer it’s worth discussing this with your GP.”
We have launched our ‘Never Too young’ campaign to raise awareness of bowel cancer in patients under the age of 50. Every year 2,100 younger people are diagnosed with bowel cancer in the UK, of which 21 are in their teens. Currently too many are being diagnosed late when treatment is harder and too many lives are needlessly being lost from this treatable disease.